Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 43598-354

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 43598-354). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Lurasidone Hydrochloride Tablets 20 mg film-coated tablets packaging label. The carton displays dosage strength, quantity (100 tablets, 10 x 10 unit-dose), and includes storage and usage instructions. Labeler is Dr. Reddy's Laboratories Inc. The label indicates the tablets are for oral use and includes a barcode and batch information section.*

FDA Label Image

Carton2 (Carton2)

Lurasidone Hydrochloride Tablets 40 mg film-coated oral tablets packaging label. The white carton features blue and red text highlighting the product name and strength. The label indicates 100 tablets per package, distributed by Dr. Reddy's Laboratories Inc., made in India. Storage instructions and dosage information appear on the side panels.*

FDA Label Image

Carton3 (Carton3)

Packaging label for Lurasidone Hydrochloride Tablets, 60 mg per tablet, film-coated oral tablets. The label indicates a package size of 100 tablets (10 unit-dose blisters of 10 tablets each). Labeler is Dr. Reddy's Laboratories Inc., Princeton, NJ. The label includes dosage, storage information, and a cautionary statement for dispensing with the Medication Guide.*

FDA Label Image

Carton4 (Carton4)

Packaging label for Lurasidone Hydrochloride Tablets 80 mg by Dr. Reddys Laboratories Inc. The label indicates 100 film-coated tablets per bottle, with instructions to dispense each time with a Medication Guide. Storage instructions and dosing notes are included. The product is marked Rx only and made in India.*

FDA Label Image

Container1 (Container1)

Label for Lurasidone Hydrochloride Tablets 20 mg, film-coated tablets by Dr. Reddys Laboratories Inc. The label indicates a quantity of 30 tablets, with storage instructions and dosage details. The NDC is 43598-351-30, and the label includes barcodes along with expiration and lot number placeholders.*

FDA Label Image

Container2 (Container2)

Label for Lurasidone Hydrochloride Tablets 40 mg by Dr. Reddys Laboratories Inc. The label states prescription use only, package contains 30 film-coated tablets. Storage instructions include 20°C to 25°C with excursions. Barcode and product identifiers including NDC 43598-352-30 are visible. The label includes a dispenser warning and the manufacturer address in Princeton, NJ, with mention of product origin in India.*

FDA Label Image

Container3 (Container3)

Label for Lurasidone Hydrochloride Tablets 60 mg in film-coated tablet form. The label indicates the product contains 30 tablets, is distributed by Dr. Reddy's Laboratories Inc., and shows instructions for storage and usage temperature. Includes a barcode and note to provide a medication guide with dispensing.*

FDA Label Image

Container4 (Container4)

Label for Lurasidone Hydrochloride Tablets 80 mg, film-coated oral tablets in a 30-tablet package. The label includes the NDC number 43598-354-30 and notes the product is by Dr. Reddys Laboratories Inc. Storage instructions and distributor information are printed alongside a barcode and placeholder text for serial number, expiration date, and lot number.*

FDA Label Image

Figure1 (Figure1)

A pharmacokinetic impact chart showing the fold change and 90% confidence intervals for various drugs interacting with Lurasidone hydrochloride. The chart compares change relative to lurasidone alone for Cmax and AUC with strong/moderate CYP3A4 inhibitors and inducers, including Ketoconazole, Diltiazem, Rifampin, and Lithium, illustrating their effects on Lurasidone pharmacokinetics.*

FDA Label Image

Figure2 (Figure2)

A chart depicting the fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC, Ctrough) of various interacting drugs when administered with another drug. Interacting drugs include digoxin, midazolam, oral contraceptives (ethinyl estradiol and norelgestromin), and lithium, with respective changes relative to the interactive drug alone shown on a horizontal axis from -1.0 to 1.0.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart showing fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of Lurasidone hydrochloride in populations with varying degrees of renal and hepatic impairment, as well as by gender and race. The x-axis represents change relative to reference, with points and error bars indicating variability for each subgroup.*

FDA Label Image

Structure (Structure)

Chemical structure of Lurasidone hydrochloride showing its molecular formula and arrangement, including the hydrochloride (HCl) component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.